Cancer

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 years ago

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech…

2 years ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about…

2 years ago

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced…

2 years ago

Defence’s Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

2 years ago

Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement

Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for…

2 years ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON,…

2 years ago

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

2 years ago

CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks

Bernard Coulie and Kevin Marks bring significant corporate, drug development, and compliance experience to the CMTA BoardThe CMTA Board and…

2 years ago

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs,…

2 years ago